This company is going to KICK BUTT in the diabetes world and the stock chart doesn't lie. Look at these facts:
1) Shares that came available after the initial IPO lock-out last Fall were easily absorbed and the stock plowed higher.
2) Dexcom shares have shrugged off the ABT patent infringement claims and plowed higher in response to theses frivolous BULL CRAP claims.
3) Dexcom's technology is cutting edge and the big industry players, specifically, Johnson & Johnson's Lifescan, Roche Diagnostics and Bayer better get ready to pony up cash to harness this technology or lose a tremendous market share opportunity in the $6 billion plus testing market.